|
Shopping Cart
Your Cart is currently empty.
Member Login
Sponsors & Partners
Acta Gastroenterologica Belgica is supported by grants
from its major sponsors
Acta Gastro-Enterologica Belgica is published in
partnership with the following national societies
Review
Dysplasia and colorectal cancer in inflammatory bowel disease : a result of inflammation or an intrinsic risk ?Price: €10,00 |
|
| Abstract
Patients with inflammatory bowel disease (IBD) face an
increased lifetime risk of developing colorectal cancer (CRC).
Although CRC in IBD only accounts for 1-2% of all cases of CRC
in the general population, it is responsible for approximately 15%
of the mortality of patients with Crohn’s disease (CD) and ulcerative
colitis (UC). Independent factors associated with increased
risk include long disease duration, extensive colonic involvement,
young age at onset of IBD, severity of inflammation, primary
sclerosing cholangitis, backwash ileitis and a family history of
CRC. Many of these factors emphasise the role of inflammation as
an underlying mechanism. Despite the differences between the
molecular abnormalities found in colitis-associated dysplasia in
comparison with sporadic CRC, IBD-associated cancer has a
similar dysplasia-cancer sequence, similar frequencies of major
chromosomal abnormalities, microsatellite instability and similar
glycosylation changes. These similarities seem to outweigh the
differences and make it reasonable to suggest that not only IBDassociated
CRC but even sporadic colon cancer might be largely
secondary to inflammation. Oxidative stress, apoptosis, COX-2
activity and a possible common inherited defective glycosylation
are thought to play a key role in the pathogenesis of colitis-associated
CRC. DNA alterations initiated in colonic crypts can expand
to adjacent crypts through crypt fission.
There seems little doubt that the increased risk of cancer in
inflammatory bowel diseases is a result of the disease rather than
an inherited phenomenon. An understanding of the definition and
pathogenesis of CRC in IBD is crucial to optimise patient management.
Further investigation is therefore necessary. (Acta gastro -
enterol. belg., 2008, 71, 367-372). [Product Details...] |
|
Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin colorectal originPrice: €10,00 |
|
| Abstract
A subset of patients with colorectal cancer (CRC) develops
synchronous or metachronous isolated peritoneal disease. The
development of peritoneal carcinomatosis (PC) can be concep -
tualized as a series of well defined steps including cell shedding,
adhesion to mesothelial cells and underlying matrix, and invasion
of submesothelial tissue. Surgical cytoreduction combined with
hyperthermic intraperitoneal chemoperfusion (HIPEC) has
evolved as the standard of care in patients with mucinous appendiceal
tumors including the pseudomyxoma peritonei syndrome.
Recently, this approach was extended to patients with peritoneal
carcinomatosis (PC) from non appendiceal CRC. In this review, we
discuss the biological rationale, clinical methods, and oncological
outcomes associated with cytoreduction and intracavitary
chemotherapy in CRC patients suffering from peritoneal disease
spread. (Acta gastro enterol. belg., 2008, 71, 373-378). [Product Details...] |
|
The role of oral fluoropyramidines in the treatment of advanced gastric cancerPrice: €10,00 |
|
| Abstract
Although the incidence of gastric cancer is declining during the
second half of the 20th century, it remains the second leading cause
of cancer death worldwide.
The majority of patients with gastric cancer will require palliative
treatment at some point in the course of their disease.
Approximately 50% of patients already have advanced incurable
disease at the time of initial presentation, and even those who
undergo potentially curative resection have high rates of distant as
well as local recurrence.
Chemotherapy in advanced gastric cancer demonstrated a significant
survival benefit over best supportive care alone. Median
overall survival increased from 3-5 to 8-12 months.
Today, a platinum based regimen is considered as first-line
treatment in advanced gastric cancer. Different regimens are
investigated and used in routine practice.
Similarly to fluorouracil, capecitabine is well tolerated in combination
with a range of cytotoxic drugs. As a single agent, it has not
undergone large scale randomised studies. S-1, another oral fluoropyrimidine,
is a potential challenger to the role of capecitabine,
but is lacking phase III data in Western population. (Acta gastro -
enterol. belg., 2008, 71, 361-366). [Product Details...] |
|
- «« Start
- « Prev
- 1
- Next »
- End »»
Acta Gastro-Enterologica Belgica is indexed in NCBI/PubMed.
Printed by Universa Press, Wetteren, Belgium. ©vzw/asbl Acta Gastro-Enterologica Belgica
Printed by Universa Press, Wetteren, Belgium. ©vzw/asbl Acta Gastro-Enterologica Belgica